Proteomic Analysis of Human Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Meng-Tzu Weng, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01177631
First received: June 2, 2009
Last updated: February 4, 2016
Last verified: February 2016
  Purpose
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

Condition Intervention
Carcinoma, Hepatocellular
Procedure: Operation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis

Resource links provided by NLM:


Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • Recurrence [ Time Frame: one year ] [ Designated as safety issue: No ]
    Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.


Enrollment: 5
Study Start Date: February 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Operation
    Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Arm A: Hepatocellular carcinoma with vessel invasion:

  • hepatocellular carcionoma, pathologic diagnosed.
  • image documented vessel invasion, including portal vein thrombosis
  • eligible for surgical intervension.

Arm B: hepatocellular carcinoma without vessel invasion:

  • hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
  • no vessel invasion on image.

Arm C: Healthy hepatitis carrier:

  • patients age >18 years old with hepatitis B or C
  • normal liver function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177631

Locations
Taiwan
Far Eastern Memorial Hospital
Taipei, Taiwan, 220
Sponsors and Collaborators
Far Eastern Memorial Hospital
  More Information

No publications provided

Responsible Party: Meng-Tzu Weng, Physician, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01177631     History of Changes
Other Study ID Numbers: 97068 
Study First Received: June 2, 2009
Last Updated: February 4, 2016
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Far Eastern Memorial Hospital:
Carcinoma, hepatocellular
Portal vein
Proteomics

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on February 09, 2016